Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index; 37 of the 150 sources its claims cite were checked for support.

Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis

Open access
Hong, Du, Zhang, Chi, Wu, Wenshuo, Lu, Xiaohui, Zhang, Liping · 2023 · Frontiers in Neurology

Abstract

There are trillions of different microorganisms in the human digestive system. These gut microbes are involved in the digestion of food and its conversion into the nutrients required by the body. In addition, the gut microbiota communicates with other parts of the body to maintain overall health. The connection between the gut microbiota and the brain is known as the gut–brain axis (GBA), and involves connections via the central nervous system (CNS), the enteric nervous system (ENS), and endocrine and immune pathways. The gut microbiota regulates the central nervous system bottom-up through the GBA, which has prompted researchers to pay considerable attention to the potential pathways by which the gut microbiota might play a role in the prevention and treatment of amyotrophic lateral sclerosis (ALS). Studies with animal models of ALS have shown that dysregulation of the gut ecology leads to dysregulation of brain–gut signaling. This, in turn, induces changes in the intestinal barrier, endotoxemia, and systemic inflammation, which contribute to the development of ALS. Through the use of antibiotics, probiotic supplementation, phage therapy, and other methods of inducing changes in the intestinal microbiota that can inhibit inflammation and delay neuronal degeneration, the clinical symptoms of ALS can be alleviated, and the progression of the disease can be delayed. Therefore, the gut microbiota may be a key target for effective management and treatment of ALS.

Overview

CoChat Summary

TL;DR

This narrative review argues that gut microbiota dysbiosis contributes to ALS through gut–brain axis mechanisms including intestinal barrier impairment, endotoxemia, neuroinflammation, immune dysregulation, and altered autophagy. It surveys preclinical and human evidence and proposes microbiota-targeted strategies—probiotics, diet, FMT, antibiotics/postbiotics, phage therapy, carbon nanoparticles, and intestinal mucosal resurfacing—as potential ALS treatments.

Key findings

  • The review links ALS to gut–brain axis dysfunction: dysbiosis, impaired intestinal barrier, endotoxemia, systemic inflammation, immune activation, and autophagy dysregulation are proposed to promote motor neuron degeneration. In SOD1G93A mice, intestinal permeability analysis showed a two-fold increase in FITC-dextran fluorescence versus wild-type mice, and dysbiosis appeared before neuromuscular symptoms.
  • Human and genetic evidence cited includes a GWAS of 20,806 ALS patients and 59,804 controls associating Enterobacteriaceae and unclassified Acidaminococcaceae with higher ALS risk; Blacher et al. found significant gut flora differences in 37 ALS patients versus 29 healthy BMI- and age-matched family members; Fang et al. reported reduced Firmicutes/Bacteroidetes ratio and altered Dorea, Oscillibacter, Anaerostipes, and Lachnospiraceae in six ALS patients.
  • Microbial metabolites are central: SCFAs are mainly acetate (40%–60%), propionate (20%–25%), and butyrate (15%–20%); butyrate is said to regulate expression of 5%–20% of human genes. LPS/TLR4 signaling, TDP-43 aggregation, and pro-inflammatory cytokines are implicated in neuroinflammation and ALS pathogenesis.
  • Therapeutic modulation in animal models includes oxalate extending ALS mouse lifespan by an average of 38 days, butyrate reducing abnormal Paneth cells and restoring lysozyme 1 and defensin 5α, and Akkermansia muciniphila alleviating ALS symptoms while Ruminococcus torques and Parabacteroides distasonis exacerbated them.

Methods

  • Design: narrative review of the gut–brain axis, gut microbiota dysbiosis in ALS, and microbiota-targeted treatment strategies.
  • Data/sample: no primary data; synthesizes animal models (e.g., SOD1G93A, C9ORF72, TDP-43 mice), human observational and clinical studies, and prior reviews, including cited samples such as 37 ALS patients/29 controls, six ALS patients, and a 20,806-patient/59,804-control GWAS.
  • Analysis: thematic synthesis of mechanistic pathways and potential therapies; no systematic search strategy, inclusion criteria, or meta-analysis is described.

Limitations

  • The paper does not state limitations.
  • Evident from the text: it is a narrative review without a described systematic search, inclusion criteria, or risk-of-bias assessment.
  • Evident from the text: much of the evidence is preclinical or from small human studies, and clinical translation of microbiota-targeted ALS therapies remains speculative.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fneur.2023.1133546

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The GBA is a bidirectional communication pathway between the gut and the CNS involving multiple feedback loops. Changes in the gut microbiota lead to alterations in the intestinal epithelial barrier, and the gut microbiota produces a variety of neuroactive metabolites, including SCFAs, neurotransmitters, and endotoxins. These factors affect autophagy, activate an immune response, and lead to dysregulation of the GBA via the ascending pathway from the gut to the brain, triggering neuroinflammation and neurodegenerative diseases of the central nervous system, such as ALS, AD, and PD. A potential avenue for treatment of ALS may involve manipulation of the gut microbiota and its derivatives, including via intestinal mucosal resurfacing, dietary intervention, probiotic supplementation, antibiotics, and post-antibiotic therapy, among other potential methods.
Figure 1 The GBA is a bidirectional communication pathway between the gut and the CNS involving multiple feedback loops. Changes in the gut microbiota lead to alterations in the intestinal epithelial barrier, and the gut microbiota produces a variety of neuroactive metabolites, including SCFAs, neurotransmitters, and endotoxins. These factors affect autophagy, activate an immune response, and lead to dysregulation of the GBA via the ascending pathway from the gut to the brain, triggering neuroinflammation and neurodegenerative diseases of the central nervous system, such as ALS, AD, and PD. A potential avenue for treatment of ALS may involve manipulation of the gut microbiota and its derivatives, including via intestinal mucosal resurfacing, dietary intervention, probiotic supplementation, antibiotics, and post-antibiotic therapy, among other potential methods.CC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 8 Not valid · 92 Not checked · 18 Own results and interpretations

51 more claims · 8 with their cited sources checked

Create a free account to see all 138 claims and to verify the 113 references still open.

See all claims — free account
  • It may state two separate claims as one. 73
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 126 references

Research works printed but not linked: 1

  1. Zhang, 2021, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi., 37, 657, 10.13423/j.cnki.cjcmi.009231 · doi:10.13423/j.cnki.cjcmi.009231

Cited by

See all 38

Metadata

Authors
Hong, D., Zhang, C., Wu, W., Lu, X., & Zhang, L.
Affiliations
  • Zhejiang Chinese Medical University (CN)
  • Sir Run Run Shaw Hospital (CN)
Corresponding author
Zhang, Liping
Venue
Frontiers in Neurology
Published
2023-04-20
Volume
14
Pages
1133546-1133546
ISSN
1664-2295 (ISSN-L)
OpenAlex
W4366586821
Cited by
38
References
126
Citations by year
2026: 10 · 2025: 12 · 2024: 13 · 2023: 3
FWCI
1.00
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
gut-brain axis, gut microbiota, amyotrophic lateral sclerosis, dysbiosis, endotoxemia, intestinal barrier, systemic inflammation, probiotics, phage therapy, antibiotics, neurodegeneration, enteric nervous system, animal models of ALS

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.3389/fneur.2023.1133546
The paper
Hong, D., Zhang, C., Wu, W., Lu, X., & Zhang, L. (2023). Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis. Frontiers in Neurology. https://doi.org/10.3389/fneur.2023.1133546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.